Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 170,400 shares, a decline of 56.9% from the August 15th total of 395,600 shares. Currently, 14.2% of the shares of the company are short sold. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is currently 0.2 days.

Ainos Stock Performance

Shares of AIMD traded up $0.01 during mid-day trading on Friday, hitting $0.53. 27,072 shares of the company’s stock were exchanged, compared to its average volume of 1,083,309. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.48 and a quick ratio of 1.45. Ainos has a fifty-two week low of $0.48 and a fifty-two week high of $4.32. The business’s 50 day moving average is $0.65 and its two-hundred day moving average is $0.92.

Ainos (NASDAQ:AIMD) last announced its earnings results on Monday, August 5th. The company reported ($0.49) earnings per share for the quarter. Ainos had a negative net margin of 15,348.14% and a negative return on equity of 64.54%.

About Ainos

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.